HC Wainwright & Co. reiterated coverage on XOMA with a new price target

10/8/21 6:18:28 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

HC Wainwright & Co. reiterated coverage of XOMA with a rating of Buy and set a new price target of $69.00 from $56.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XOMA

Date	Price Target	Rating	Analyst
4/17/2025	$35.00	Buy	The Benchmark Company
4/29/2024	$40.00	Outperform	Leerink Partners
10/8/2021	$56.00 → $69.00	Buy	HC Wainwright & Co.
9/9/2021	$60.00 → $56.00	Buy	Aegis Capital
9/7/2021	$22.00	Outperform → Neutral	Wedbush
9/7/2021	$22.00	Neutral → Underperform	Wedbush
6/29/2021	$60.00	Buy	Aegis Capital